title: [First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)].
authors.affiliation: MeckEvidence, Seestraße 11, 17252 Schwarz, Deutschland. AUO@MeckEvidence.de
authors.forename: H
authors.initials: H
authors.lastname: Rexer
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage* / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D000077157:Sorafenib; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D001557:Benzenesulfonates; D007191:Indazoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011743:Pyrimidines; D013449:Sulfonamides; D009536:Niacinamide; C516667:pazopanib; D000077157:Sorafenib